Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
Globe Newswire•26/10/2026•07:00 ET
0
Key Highlights
- ➤Tonix to report Q3 2026 financial results and operational highlights November 9
- ➤TONMYA is the first fibromyalgia treatment in more than 15 years
- ➤Tonix markets Zembrace SymTouch and Tosymra acute migraine products
- ➤TNX-4800 is Phase 2-ready for Lyme disease prevention
- ➤TNX-1500 is Phase 2-ready for kidney transplant rejection prevention
BERKELEY HEIGHTS, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company, today announced that it will host a conference call and webcast to report third quarter 2026 financial results and operational highlights on Monday, November 9, 2026, at 8:30 a.m. ET.
To listen to the conference call, register at this link. To view the webcast, register at this link.
Get started
Create a free account to read the full story.